
Yelena Y Janjigian MD: PD-1 Blockade Directed by ctDNA Delayed Recurrence in Mismatch Repair Deficient Solid Tumors After Surgery and Standard of Care
Yelena Y Janjigian MD talks about the use of ctDNA to direct immunotherapy among patients with mismatch repair deficient solid tumors.
An interview with:
Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.
CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (PD-1) immunotherapy with pembrolizumab after surgery and standard of care if they tested positive for circulating tumor DNA (ctDNA).
These findings come from a phase two clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. Audio Journal of Oncology correspondent Peter Goodwin talked with first author of the study: Yelena Y Janjigian MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New York.
INTERVIEW: Yelena Y Janjigian, MD
AACR ABSTRACT Title:
Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors
Next in AACR 2025
All 14 interviewsInterview 6 of 14

Paolo Marchetti MD: Tissue or Liquid Biopsy? Both Together Could Be Best for Advanced Solid Tumor Therapy Planning
Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome
Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca